Oncology Nursing Society Congress

Anne Katz, from the University of Manitoba, Discusses Cancer and Sexuality

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Jayshree Shah, from John Theurer Cancer Center, on the Safety and Efficacy of Nilotinib for Patients With CML

Kim Kelly, from John Theurer Cancer Center, on the Updated MASCC/ISOO Clinical Practice Guidelines for Mucositis

With four full days of programming, dozens of exhibitors, satellite symposia, and thousands of members in attendance, trying to fit everything in at the ONS Annual Congress can prove quite challenging.

This year's ONS Annual Congress marks the first at which Mary Gullatte, PhD, RN, APRN, BC, AOCN, will serve as the organization's president.

Meeting coverage from the 2012 Oncology Nursing Society Congress held at the New Orleans Ernest N. Morial Convention Center, from May 3-6, 2012.

Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Oral oncolytics are frequently used in cancer treatment and they make up approximately 25% of the medications in the oncology pipeline

Honorary Mistress of Ceremonies Cynthia Nixon kicked off the ONS 36th Annual Congress Cure magazine Extraordinary Healer Award with a rousing tribute

Lymphedema is the treatment-induced buildup of extra lymph fluid in tissues that causes discomforting and potentially debilitating swelling of the limbs

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

Social media programs allow oncology nurses to network, share information, and learn evidence-based practices

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

Elizabeth Blasiak on the Significance of the ONS Congress

Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals